Bayer: Darolutamid plus ADT und Strahlentherapie senkt Metastasen- oder Sterberisiko bei Prostatakrebs um 58 Prozent
- Bayer hat Ergebnisse zu Darolutamid veröffentlicht: In Kombination mit ADT und Strahlentherapie sinkt bei Prostatakrebspatienten mit hohem Rückfallrisiko das Metastasen- oder Sterberisiko.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.